A pilot study of ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation

Transplantation

Volumn 61, Issue 10, 1996, Pages 1483-1488

  Cattral, Mark S ^a,b   Krajden, Mel ^a   Wanless, Ian R ^a   Rezig, Mohammed ^a   Cameron, Ross ^a   Greig, Paul D ^a   Chung, Stephen W ^a   Levy, Gary A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; RIBAVIRIN;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; FEMALE; GRAFT SURVIVAL; HEMOLYSIS; HEPATITIS; HEPATITIS C; HUMAN; HUMAN TISSUE; JAUNDICE; LIVER BIOPSY; LIVER TRANSPLANTATION; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SURVIVAL; VIRUS INFECTION;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PILOT PROJECTS; RECURRENCE; RIBAVIRIN; RNA, VIRAL;

EID: 0029895514     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199605270-00013     Document Type: Article

References (28)

1. Feray C, Samuel D, Thiers V, et al. Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest 1992; 89: 1361.
2. Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103: 317.
3. Feray C, Gigou M, Samuel D, et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994; 20: 1137.
4. Sheiner PA, Schwartz ME, Mor E, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30.
5. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C- A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506.
6. Wright TL, Combs C, Kim M, et al. Interferon-α therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994; 20: 773.
7. Wright HI, Gavler JS, Van Thiel DH. Preliminary experience with α-2b-interferon therapy of viral hepatitis in liver allograft recipients. Transplantation 1992; 53: 121.
8. Patterson JL and Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990; 12: 1139.
9. Dusheiko G, Weiland O, Thomas H, et al. Results of a placebo-controlled study of ribavirin in patients with chronic hepatitis C. Hepatology 1994; 20: 206A.
10. Bodenheimer HC, Lindsay KL, Davis GL, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology 1994; 20: 207A.
11. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431.
12. Quan CM, Krajden M, Zhao J, Chan AW. High-performance liquid chromatography to assess the effect of serum storage conditions on the detection of hepatitis C virus by the polymerase chain reaction. J Virol Methods 1992; 43: 299.
13. Bukh J, Purcell RH, Miller RH. Importance of primer selection for the detection of hepatitis C virus RNA with the polymerase chain reaction. Proc Natl Acad Sci 1992; 89: 187.
14. Davis GL, Lau JYN, Urdea MS, et al. Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 1994; 19: 1337.
15. Gane EJ, Tibbs CJ, Ramage JK, Portmann BC, Williams R. Ribavirin therapy for hepatitis C infection following liver transplantation. Transplant Int 1995; 8: 61.
16. Shiffman ML, Contos MJ, Luketic VA, et al. Biochemical and histologic evaluation of recurrent hepatitis C following orthotopic liver transplantation. Transplantation 1994; 57: 526.
17. Sheiner PA, Fisher A, Schluger LK, et al. Treatment with α-interferon does not alter the course of recurrent hepatitis C. Hepatology 1994; 20: 133A.
18. Wright TL and Pereira B. Liver transplantation for chronic viral hepatitis. Liver Transplant Surg 1995; 1: 30.
19. Di Bisceglie AM, Shindo M, Fong TL, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992; 16: 649.
20. Di Biscelgie AM, Bacon BR, Kleiner DE, Hoofnagle JH. Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. J Hepatol 1994; 21: 1109.
21. Olynyk JK, Reddy KR, Di Bisceglie AM, Jeffers LJ, Parker TI, Radick JL. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995; 108: 1104.
22. Britton RS, Ramm GA, Olynyk J, Singh R, O'Neill R, Bacon BR. Pathophysiology of iron toxicity. Adv Exp Med Biol 1994; 356: 239.
23. Reichard O, Yun ZB, Sonnerborg A, Weiland O. Hepatitic C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. J Med Virol 1993; 41: 99.
24. Heagy W, Crumpacker C, Lopez PA, Finberg RW. Inhibition of immune functions by antiviral drugs. J Clin Invest 1991; 87: 1916.
25. Jolley WB, Sharma B, Charni R, Ng C, Bullington R. Long-term skin allograft survival by combined therapy with suboptimal dose of cyclosporine and ribavirin. Transplant Proc 1988; 20: 703.
26. Brillanti S, Garson J, Foli M, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107: 812.
27. Pereira BJG, Milford EL, Kirkman RL, et al. Prevalence of HCV RNA in hepatitis C antibody positive cadaver organ donors and their receipients. N Engl J Med 1992; 327: 910.
28. Pereira BJG, Wright TL, Schmid CH, et al. A controlled trial of hepatitis C transmission by organ transplantation. Lancet 1995; 345: 484.